Over the last six decades in the U.S., gastric, or stomach, cancer rates have plummeted. But around the world, gastric cancer remains a leading cause …
Brain tumors are among the most deadly and difficult-to-treat cancers. Glioblastoma, a particularly aggressive form, kills more than 10,000 Americans a year and has a …
Researchers from Stanford have developed a wearable sensor to monitor the size of tumors, which could assist new cancer drug evaluations.
Research into the destructive influence tiny DNA circles have on cancer presents endless ideas for clearly describing groundbreaking science.
A group of Black women work toward a peer navigation program to help other Black women survive breast cancer.
Stanford Medicine magazine explores the molecules behind human biology and how understanding them fuels medical discoveries and innovations.
Researchers are using data science to home in on therapies that will work best for specific patients, advancing precision oncology.
Scientists used a mobile app to screen elderly patients for potential skin cancer lesions, pointing to the value of digital health tools.
Researchers at Stanford Medicine discover a certain molecule renders a type of cancer cell more susceptible to treatment.
While melanoma rates have leveled off for most of the United States, Black and Latino communities are at a higher risk for the disease.
Research from early clinical trials of pediatric glioma patients shows that altered immune cells can fight the deadly brainstem tumor.
The common antidepressant Prozac melts away glioblastoma tumors in laboratory mice, suggesting possible treatment for the deadly cancer.
Neurosurgeon Michael Lim studies how to unleash the immune system to attack a type of brain cancer called glioblastoma.
A common ovarian cancer evades detection by convincing nearby immune cells to treat it as a developing fetus.
Stanford Medicine researchers conducted an experiment to find new genes that, when knocked out, boost immune cells' cancer-killing ability.
Stanford Medicine Scientists have devised a blood test to predict some cancer relapses after patients have already been treated.